InvestorsHub Logo
Followers 51
Posts 1681
Boards Moderated 0
Alias Born 02/15/2007

Re: horselover45 post# 105464

Friday, 12/28/2012 4:09:46 PM

Friday, December 28, 2012 4:09:46 PM

Post# of 345969
Andy, it was mentioned in the PR from the quarterly report on Dec 10th.
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=725936

PRECLINICAL DEVELOPMENT HIGHLIGHTS
In October, at the 27th Annual Meeting of the Society for Immunotherapy of Cancer, data were presented demonstrating the ability of the company's PS-targeting antibodies to stimulate cancer fighting immune responses.
Additionally, data were published in the peer-reviewed journal Nuclear Medicine and Biology highlighting results from a study investigating the company's fully human phosphatidylserine (PS)-targeting antibody PGN635 utilized as a radiolabeled tumor imaging probe. The results demonstrate the potential breadth of applicability of the company's PS-targeting antibodies to clearly image solid tumors regardless of cancer type, and provide a potential method to rapidly assess the anti-tumor efficacy of chemotherapies and other approved and experimental cancer treatments.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News